PROGRAM CHAIR
David Planchard, MD, PhD
Department of Medical Oncology
Institut Gustave Roussy
Head of Thoracic Cancer Group
Thoracic Group
Villejuif, France
PROGRAM DESCRIPTION
In this brief 30-minute program, noted global expert in lung cancer, Dr. David Planchard, MD, PhD, head of the thoracic cancer group at Gustave Roussy in Villejuif, France, will describe current data informing the management of advanced NSCLC. Based on current clinical evidence, updated guidelines inform the selection of checkpoint inhibition and combinations of checkpoint inhibitors with chemotherapy in the frontline setting. Through appropriate selection of patients for single-agent versus combination regimens in the frontline setting of advanced NSCLC lacking targetable mutations, and awareness of potential adverse events associated with therapy, clinicians will be better equipped to improve therapeutic outcomes for patients.
TARGET AUDIENCE
This activity is designed to meet the educational needs of global oncologists, oncology nurses, pharmacists, nurse practitioners, and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
LEARNING OBJECTIVES
- Apply mono immunotherapy clinical trials data in the first-line treatment of patients with advanced NSCLC with no targetable mutations
- Review the clinical trials data for combinations of immune checkpoint inhibitors and chemotherapy in the first-line management of patients with advanced NSCLC
- Evaluate the application of clinical practice guidelines to the first-line treatment of patients with advanced NSCLC without targetable mutations
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 0.50 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
| David Planchard, MD, PhD | Consulting, advisory role or lectures: | AstraZeneca, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Janssen, Pfizer, Roche, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen |
| Clinical trials research as principal or co-investigator (Institutional financial interests): | AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, Abbvie, Janssen, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen | |
| Travel, Accommodations, Expenses: | AstraZeneca, Roche, Novartis, Pfizer |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Michael R. Page, PharmD, RPh Medical Director for Med Learning Group, discloses an ownership stake in Advantific, LLC.
- Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
